J Dent Rehabil Appl Sci.  2019 Dec;35(4):199-205. 10.14368/jdras.2019.35.4.199.

A proposal for management of migraine in dental clinic

• Park Y
• Lee HJ
• Kim ST

• KMID: 2470624
• DOI: http://doi.org/10.14368/jdras.2019.35.4.199

Abstract

Management of migraine, one of common primary headache disorders, involves the diverse strategies non-pharmacological treatment, such as headache diary, lifestyle modification, regular exercise and relaxation, cognitive behavioral therapy and neurostimulation, and pharmacological treatment. Among the treatments, this review described a pharmacologic treatment of migraine, classified into acute and preventive treatment based on the severity and the frequency of headache. It introduced the way to optimize pharmacological treatment and updated the latest treatment for migraine.

Keyword

migraine; treatment; acute; preventive; principles

MeSH Terms

Cognitive Therapy
Dental Clinics*
Headache
Headache Disorders, Primary
Life Style
Migraine Disorders*
Relaxation

Figure

• 

  Fig. 1 This Allergan figure shows the injection sites for dispersing the 155U of OnabotulinumtoxinA.14

• 

  Fig. 2 Electrical trigeminal nerve stimulation, Cefaly® device.15

Reference

References

1. Lee TG CK, Chung KC, Choi JW. 2000; Prevalence of migraine in Korean adults: a nationwide survey. Korean J Headache. 1:57–66.

2. Headache Classification Committee of the International Headache Society (IHS). 2018; The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 38:1–211. DOI: 10.1177/0333102417738202. PMID: 29368949.

3. Lee HJ, Kim YG, Kim ST. 2016; Diagnosis of headaches in dental clinic. J Dent Rehabil Appl Sci. 32:102–8. DOI: 10.14368/jdras.2016.32.2.102.

4. Kim BK, Cho SJ, Kim BS, Sohn JH, Kim SK, Cha MJ, Song TJ, Kim JM, Park JW, Chu MK, Park KY, Moon HS. 2016; Comprehensive Application of the International Classification of Headache Disorders Third Edition, Beta Version. J Korean Med Sci. 31:106–13. DOI: 10.3346/jkms.2016.31.1.106. PMID: 26770045. PMCID: PMC4712567.

5. Brennum J, Brinck T, Schriver L, Wanscher B, Sorensen PS, Tfelt-Hansen P, Olesen J. 1996; Sumatriptan has no clinically relevant effect in the treatment of episodic tension-type headache. Eur J Neurol. 3:23–8. DOI: 10.1111/j.1468-1331.1996.tb00184.x.

6. Silberstein SD. 2000; Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 55:754–62. DOI: 10.1212/WNL.55.6.754. PMID: 10993991.

7. Marmura MJ, Silberstein SD, Schwedt TJ. 2015; The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 55:3–20. DOI: 10.1111/head.12499. PMID: 25600718.

8. Laurell K, Artto V, Bendtsen L, Hagen K, Haggstrom J, Linde M, Soderstrom L, Tronvik E, Wessman M, Zwart JA, Kallela M. 2016; Premonitory symptoms in migraine: A cross-sectional study in 2714 persons. Cephalalgia. 36:951–9. DOI: 10.1177/0333102415620251. PMID: 26643378.

9. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Advisory Group. 2007; Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 68:343–9. DOI: 10.1212/01.wnl.0000252808.97649.21. PMID: 17261680.

10. Ashkenazi A, Blumenfeld A. 2013; OnabotulinumtoxinA for the treatment of headache. Headache. 53(Suppl 2):54–61. DOI: 10.1111/head.12185. PMID: 24024603.

11. Steiner TJ, Gobel H, Jensen R, Lampl C, Paemeleire K, Linde M, Braschinsky M, Mitsikostas D, Gil-Gouveia R, Katsarava Z; European Headache Federation and Lifting The Burden: the Global Campaign against Headache. 2019; Headache service quality: the role of specialized headache centres within structured headache services, and suggested standards and criteria as centres of excellence. J Headache Pain. 20:24. DOI: 10.1186/s10194-019-0970-7. PMID: 30832585. PMCID: PMC6734362.

12. Stewart WF, Lipton RB, Dowson AJ, Sawyer J. 2001; Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 56:S20–8. DOI: 10.1212/WNL.56.suppl_1.S20. PMID: 11294956.

13. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. 2012; Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 78:1337–45. DOI: 10.1212/WNL.0b013e3182535d20. PMID: 22529202. PMCID: PMC3335452.

14. BOTOX®. Allergan I, editor. 2010. Chronic Migraine Reconstitution and Injection Workshop Guide.

15. Cefaly. Available from: https://www.cefaly.us/en/migraine-treatment-cefaly. (Updated 2019 Sep 4).